David Nierengarten

May 15, 2026

David Nierengarten rated STRO as Outperform on May 15, 2026, setting a price target of 60. Shares have remained stable near 38.97, leaving the 60 target still in play.

May 08, 2026

STTK received a Outperform rating from David Nierengarten on May 08, 2026, aiming for 11. The rating hasn’t played out as hoped, with the stock trading 8.61% below expectations.

May 05, 2026

On May 05, 2026, David Nierengarten published a Outperform outlook on NUVB, with a target of 11. Market action contradicted the Buy thesis, as shares slipped to 4.32.

May 05, 2026

David Nierengarten on May 05, 2026 assigned CATX a Outperform rating, with a price target of 11. The Buy call aligned well with market performance, producing a gain of 5.48%.

Apr 29, 2026

On Apr 29, 2026, David Nierengarten reaffirmed KNSA with a Outperform rating, targeting 59. The recommendation was supported by strong follow-through as the stock rose from 56.51 to 56.51.

Apr 16, 2026

On Apr 16, 2026, David Nierengarten initiated coverage on FENC with a Outperform rating and target of 13. The stock’s climb of 54.76% since the call highlights the foresight in the rating.

Apr 14, 2026

David Nierengarten issued a Outperform recommendation for SYRE on Apr 14, 2026, price target set at 80. Investors following the Buy call captured upside momentum, with shares now at 74.92.

Apr 13, 2026

On Apr 13, 2026, TLX was evaluated by David Nierengarten, who gave a Outperform rating and target of 22. Investors saw limited payoff as shares fell short of the 22 target.

Apr 08, 2026

David Nierengarten rated NUVL as Outperform on Apr 08, 2026, setting a price target of 125. Shares have remained stable near 102.3, leaving the 125 target still in play.

Apr 01, 2026

On Apr 01, 2026, SRRK was given a Outperform rating by David Nierengarten, with a target price of 58. The stock traded sideways with a 0.00% move, keeping the bullish thesis unresolved.

Apr 01, 2026

ORIC received a Outperform rating from David Nierengarten on Apr 01, 2026, aiming for 17. Momentum has favored the Buy call, with shares climbing from 8.15 to 8.15, rewarding those who trusted the recommendation.

Mar 31, 2026

On Mar 31, 2026, David Nierengarten published a Outperform outlook on BCAX, with a target of 30. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 20.23.

Mar 17, 2026

David Nierengarten on Mar 17, 2026 assigned COGT a Outperform rating, with a price target of 55. The call has struggled to gain traction, with shares losing 7.74%.

Mar 09, 2026

On Mar 09, 2026, David Nierengarten reaffirmed ARGX with a Outperform rating, targeting 1. The recommendation was supported by strong follow-through as the stock rose from 799.32 to 799.32.

Mar 05, 2026

TCRX was rated Outperform by David Nierengarten on Mar 05, 2026, with a price objective of 5. The stock is in a wait-and-see zone, leaving the Buy case open-ended.

Mar 03, 2026

On Mar 03, 2026, David Nierengarten initiated coverage on APGE with a Outperform rating and target of 95. The stock’s climb of 18.45% since the call highlights the foresight in the rating.

Feb 25, 2026

David Nierengarten issued a Outperform recommendation for BEAM on Feb 25, 2026, price target set at 65. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

Feb 17, 2026

David Nierengarten rated IRON as Outperform on Feb 17, 2026, setting a price target of 110. Shares have remained stable near 66.86, leaving the 110 target still in play.

Jan 15, 2026

On Jan 15, 2026, IMNM was given a Outperform rating by David Nierengarten, with a target price of 31. Despite the Buy call, shares fell from 20.88 to 20.88, challenging the optimistic stance.

Dec 16, 2025

GBIO received a Outperform rating from David Nierengarten on Dec 16, 2025, aiming for 7. Price action was muted, as shares hovered around 5.34 despite the bullish outlook.

Dec 11, 2025

On Dec 11, 2025, David Nierengarten published a Outperform outlook on BBOT, with a target of 25. Market action contradicted the Buy thesis, as shares slipped to 8.51.

Oct 27, 2025

David Nierengarten on Oct 27, 2025 assigned FATE a Outperform rating, with a price target of 7. The Buy call aligned well with market performance, producing a gain of 13.23%.

Oct 15, 2025

On Oct 15, 2025, David Nierengarten reaffirmed ANAB with a Outperform rating, targeting 70. The recommendation was supported by strong follow-through as the stock rose from 63.15 to 63.15.

Sep 02, 2025

XNCR was rated Outperform by David Nierengarten on Sep 02, 2025, with a price objective of 26. A bullish response from the market helped close the gap of 14.78 to the target.

Feb 12, 2025

On Feb 12, 2025, SWTX was evaluated by David Nierengarten, who gave a Outperform rating and target of 77. Investors saw limited payoff as shares fell short of the 77 target.

Jan 13, 2025

David Nierengarten rated BPMC as Outperform on Jan 13, 2025, setting a price target of 124. The call has proven timely, with shares rising 25.25% toward the price target of 124.

Nov 18, 2024

On Nov 18, 2024, CMRX was given a Outperform rating by David Nierengarten, with a target price of 6. The stock rallied 870.45% after the rating, narrowing the gap to the target of 6 and validating the bullish stance.

Sep 30, 2024

INZY received a Outperform rating from David Nierengarten on Sep 30, 2024, aiming for 15. The rating hasn’t played out as hoped, with the stock trading 23.52% below expectations.

Apr 23, 2024

David Nierengarten on Apr 23, 2024 assigned PRME a Outperform rating, with a price target of 12. The call has struggled to gain traction, with shares losing 38.96%.